News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC
Jan 17, 2025, 17:53

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared on X:

“Intermittent or Continuous FOLFIRI + PANITUMUMAB RAS and BRAF Wild-Type Metastatic CRC: The IMPROVE Trial

Intermittent FOLFIRI + pani has similar outcomes in terms of PFSot and OS compared to continuous Rx. Detrimental effect in Right sided tumors.”

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Authors: Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, Giuseppe Santabarbara, Guglielmo Nasti, Vincenzo Montesarchio, Gerardo Rosati, Antonino Cassata, Silvana Leo, Carmela Romano, Emiliano Tamburini, Lucrezia Silvestro, Claudio Lotesoriere, Anna Nappi, Daniele Santini, Antonella Petrillo, Alfredo Colombo, Antonio Febbraro, Alessandra Leone, Francesco Mannavola, Maria Maddalena Laterza, Francesco Izzo, Alberto Sobrero, Paolo Delrio, Diana Giannarelli, and Alfredo Budillon.

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

 

Akhil Santhosh Alberto Sobrero Alessandra Leone Alfonso De Stefano Alfredo Budillon Alfredo Colombo Anna Nappi Antonella Petrillo Antonino Cassata Antonio Avallone Antonio Febbraro cancer Carmela Romano Claudio Lotesoriere Daniele Santini Diana Giannarelli Emiliano Tamburini Francesco Giuliani Francesco Izzo Francesco Mannavola Gerardo Rosati Giuseppe Santabarbara Guglielmo Nasti Lucrezia Silvestro Maria Maddalena Laterza OncoDaily Oncology Paolo Delrio Silvana Leo Vincenzo Montesarchio
Special Coverage
Radiotherapy
Aug 4, 2025, 01:19
Varian: Radiotherapy Giant
Blog
Aug 3, 2025, 20:47
Debanjan Kundu: I am Privileged to Have Visited This Centuries-Old Hospital as an AROI WB Young Oncology Fellow
Insight
Aug 3, 2025, 20:42
Armando Orlandi։ Redefining Who Should Consider Preventive Breast Surgery
Blog
Aug 3, 2025, 20:29
Al-Ola A Abdallah: 2nd Regional ‪2025 Immune Cell Effector Therapy Symposium Conference
Blog
Aug 3, 2025, 20:04
How the Latest Evidence Is Used in EGFR-Mutated NSCLC Treatment - NCODA
Blog
Aug 3, 2025, 19:45
Miguel Bronchud: Primary Tumor Surgery Lymphadenectomy?
Blog
Aug 3, 2025, 19:41
Hung Trinh: First-of-its-kind Clinical Trial - Reprogramming Stem Cells to Create Renewable Cancer-fighting T Cells
Insight
Aug 3, 2025, 19:32
Amol Akhade: Understanding the Hidden Rules of Trial Design
Blog
Aug 3, 2025, 19:26
Dewi Vernerey: The Results of the ASTER 70s Trial
Insight
Aug 3, 2025, 19:25
Patrick Hwu։ Why Do Some Gastrointestinal Cancers Become Resistant to KRAS-targeted Therapies?
Insight
Aug 3, 2025, 19:18
Wafaa M Rashed: Polygenic Risk Score for Cancer in African Population
Insight
Aug 3, 2025, 18:54
Ali Mortezaei: Our Study on the Cover of the Journal of Neurosurgery Publishing Group Focus